An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy

被引:39
|
作者
Liu, Ping-Yu
Alberts, David S.
Monk, Bradley J.
Brady, Mark
Moon, James
Markman, Maurie
机构
[1] Grp Stat Ctr, SW Oncol Grp, Seattle, WA USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] Gynecol Oncol Grp, Ctr Stat, Buffalo, NY USA
[5] MD Anderson Canc Ctr, Houston, TX USA
关键词
D O I
10.1200/JCO.2006.09.4540
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose For ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy, we tested the predictive value of the following early signal of progressive disease ( EPD) criterion based on serum CA-125: for patients with CA-125 nadir <= 10 U/mL, a confirmed value of >= 20 U/mL serves as an early signal of CA-125 progression; for patients with nadir more than 10 U/ mL, a value >= 2 x nadir that is confirmed predicts progression. Patients and Methods The EPD criterion was tested on Southwest Oncology Group trial 9701/Gynecologic Oncology Group trial 178 patients ( n = 288) and compared with Gynecologic Cancer Intergroup criterion. Results For 204 patients with known progressive disease, the progression date was predated by EPD by <= 60 days in 31%, 61 to 180 days in 15%, and more than 180 days in 10% ( median, 56 days early). Of 84 progression-free patients, nine EPDs were found. Overall, 135 patients met the EPD criterion. True disease progression status was undeterminable for two patients and nine were potentially false signals, for a conservative positive predictive value of 93% ( 95% CI, 88% to 97%). Conclusion Initial testing of the proposed CA-125 criterion resulted in a low false-positive rate and early prediction of disease progression in more than 50% of the patients tested. The proposed criterion may better reflect the timing of disease progression and should be investigated further.
引用
收藏
页码:3615 / 3620
页数:6
相关论文
共 50 条
  • [31] Perioperative percent change in CA-125 in patients with high grade serous ovarian cancer undergoing primary cytoreductive surgery with complete gross resection
    Hirani, Rahim
    Praiss, Aaron
    Choi, Kyung
    Gardner, Ginger
    Roche, Kara Long
    Sonoda, Yukio
    Chi, Dennis
    Zivanovic, Oliver
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S136 - S136
  • [32] THE CLINICAL-VALUE OF SERUM CA125 LEVELS IN OVARIAN-CANCER PATIENTS RECEIVING PLATINUM THERAPY
    FISH, RG
    SHELLEY, MD
    MAUGHAN, T
    ROCKER, I
    ADAMS, M
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (06): : 831 - 835
  • [33] The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer
    Rocconi, Rodney P.
    Matthews, Kellie S.
    Kemper, Meredith K.
    Hoskins, Kelly E.
    Huh, Warner K.
    Straughn, J. Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 242 - 245
  • [34] CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer
    Furukawa, Naoto
    Sasaki, Yoshikazu
    Shigemitsu, Aiko
    Akasaka, Juria
    Kanayama, Seiji
    Kawaguchi, Ryuji
    Kobayashi, Hiroshi
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (02) : 141 - 145
  • [35] Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
    Zebic, Danka Sinikovic
    Tjokrowidjaja, Angelina
    Francis, Katherine Elizabeth
    Friedlander, Michael
    Gebski, Val
    Lortholary, Alain
    Joly, Florence
    Hasenburg, Annette
    Mirza, Mansoor
    Denison, Ursula
    Cecere, Sabrina Chiara
    Ferrero, Annamaria
    Pujade-Lauraine, Eric
    Lee, Chee Khoon
    BRITISH JOURNAL OF CANCER, 2024, 130 (03) : 425 - 433
  • [36] Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
    Danka Sinikovic Zebic
    Angelina Tjokrowidjaja
    Katherine Elizabeth Francis
    Michael Friedlander
    Val Gebski
    Alain Lortholary
    Florence Joly
    Annette Hasenburg
    Mansoor Mirza
    Ursula Denison
    Sabrina Chiara Cecere
    Annamaria Ferrero
    Eric Pujade-Lauraine
    Chee Khoon Lee
    British Journal of Cancer, 2024, 130 : 425 - 433
  • [37] THE CA-125 LEVEL AFTER NEOADJUVANT CHEMOTHERAPY FOR RELAPSE FREE SURVIVAL PREDICTION IN PATIENTS WITH ADVANCED OVARIAN CANCER CANCER
    Lee, Y. J.
    Kim, Y. M.
    Lee, S. H.
    Park, J. Y.
    Suh, D. S.
    Kim, D. Y.
    Kim, J. H.
    Kim, Y. T.
    Nam, J. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1415 - 1415
  • [38] Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
    M Wilbaux
    E Hénin
    A Oza
    O Colomban
    E Pujade-Lauraine
    G Freyer
    M Tod
    B You
    British Journal of Cancer, 2014, 110 : 1517 - 1524
  • [39] Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
    Wilbaux, M.
    Henin, E.
    Oza, A.
    Colomban, O.
    Pujade-Lauraine, E.
    Freyer, G.
    Tod, M.
    You, B.
    BRITISH JOURNAL OF CANCER, 2014, 110 (06) : 1517 - 1524
  • [40] RECIST is more sensitive than CA-125 in detecting disease progression in epithelial ovarian cancer patients treated with maintenance bevacizumab: A secondary analysis of the ROSIA trial
    Lavie, O.
    Feferkorn, I.
    Frenkel, O.
    Segev, Y.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 117 - 117